Anne Li Feburary 8th, 2018
Updated results from a global clinical trial of the CAR T-cell therapy, tisagenlecleucel, a landmark personalized treatment for a high-risk form of acute lymphoblastic leukemia (ALL), reveal that children and young adults continued to show high rates of durable, complete remission of their disease. Most side effects were short-lived and reversible. Based on previous findings, the U.S. Food and Drug Administration (FDA) approved tisagenlecleucel — brand name Kymriah — in August 2017 for children and young adults up to 25 years of age with B-cell ALL that is refractory or in second or later relapse. It was the first-ever FDA-approved gene therapy, as well as the first FDA-approved CAR-T cell therapy.
See original article at: https://www.sciencedaily.com/releases/2018/01/180131230101.htm